•
Sep 30, 2021
Cencora Q4 2021 Earnings Report
AmerisourceBergen reported strong fourth quarter and fiscal year 2021 results, marked by a revenue increase of 19.6% and adjusted diluted EPS growth of 26.5%.
Key Takeaways
AmerisourceBergen's Q4 2021 revenue increased by 19.6% to $58.9 billion. GAAP diluted EPS was $2.08, while adjusted diluted EPS increased by 26.5% to $2.39. The company's performance was driven by growth in Pharmaceutical Distribution Services and the acquisition of Alliance Healthcare.
Revenue increased 19.6% to $58.9 billion for the fourth quarter.
GAAP diluted EPS was $2.08 for the fourth quarter.
Adjusted diluted EPS increased 26.5% to $2.39 for the fourth quarter.
Revenue increased 12.7% to $214.0 billion for fiscal year 2021.
Cencora
Cencora
Forward Guidance
AmerisourceBergen has introduced its fiscal year 2022 financial guidance, which reflects growth in both of its new reportable segments.
Positive Outlook
- Revenue growth in the high-single digit to low-double digit percent range
- U.S. Healthcare Solutions revenue in the range of $207 to $212 billion, representing growth of 2% to 5%
- International Healthcare Solutions revenue of approximately $26 to $27 billion
- Adjusted diluted earnings per share to be in the range of $10.50 to $10.80
- Adjusted operating income growth in the mid- to high-teens percent range
Challenges Ahead
- Interest expense growth to be in the mid-teens percent range
- Adjusted effective tax rate to be approximately 21 percent to 22 percent
- Adjusted free cash flow to be approximately $2 to $2.5 billion
- Capital expenditures in the $500 million range
- Weighted average diluted shares are expected to be approximately 212 million for the fiscal year